Table 2.

Risk of neurological and psychiatric sequelae at 6 months, risk horizon, and time to equal incidence for each diagnosis after COVID-19 versus after other respiratory infections, in the propensity-score matched population

	Hazard ratio (95% CI)	p value	Risk horizon (days)	Time to equal incidence (days)
Anxiety disorder	1·13 (1·11–1·15)	<0·0001	58	417
Cognitive deficit	1·36 (1·33–1·39)	<0·0001	NR	NR
Dementia	1·33 (1·26–1·41)	<0·0001	NR	NR
Encephalitis	0·96 (0·85–1·08)	0·50	..	..
Epilepsy or seizures	1·14 (1·09–1·19)	<0·0001	NR	NR
Guillain-Barré syndrome	1·12 (0·97–1·30)	0·12	..	..
Insomnia	1·13 (1·10–1·16)	<0·0001	90	NR
Intracranial haemorrhage	1·09 (1·01–1·18)	0·020	506	658
Ischaemic stroke	1·11 (1·06–1·17)	<0·0001	66	712
Mood disorder	1·08 (1·06–1·11)	<0·0001	43	457
Myoneural junction or muscle disease	1·89 (1·76–2·04)	<0·0001	497	NR
Nerve, nerve root, and plexus disorder	0·89 (0·87–0·91)	<0·0001	..	..
Parkinsonism	1·04 (0·92–1·17)	0·58	..	..
Psychotic disorder	1·27 (1·18–1·37)	<0·0001	NR	NR
Any first outcome	1·13 (1·11–1·15)	<0·0001	48	469

The risk horizon is the time at which the time-varying hazard ratio returns to 1 (ie, the baseline risk in the comparison cohort). The time to equal incidence is the time at which the cumulative incidences of the two cohorts become equal. The risk horizon and time to equal incidence are only included for outcomes with a significantly increased hazard ratio at 6 months; for outcomes that did not reach the risk horizon or time to equal incidence within the follow-up period (up to 730 days), they are shown as not reached (NR).